{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:31:14Z","timestamp":1784543474368,"version":"3.55.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.prrv.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:21:31Z","timestamp":1774052491000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunomodulation in paediatric inflammatory interstitial lung diseases: towards mechanism-based targeted therapies, a focus on the anti-cytokines"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1943-6237","authenticated-orcid":false,"given":"Apolline","family":"Gonsard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Fremond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Hadchouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2026.03.001_b0005","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/thorax-2023-221325","article-title":"Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort","volume":"79","author":"Fletcher","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2026.03.001_b0010","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0100-2017","article-title":"Chronic interstitial lung disease in children","volume":"27","author":"Griese","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.prrv.2026.03.001_b0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2352-4642(19)30117-8","article-title":"Children\u2019s interstitial and diffuse lung disease","volume":"3","author":"Cunningham","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.prrv.2026.03.001_b0020","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71112","article-title":"Childhood interstitial lung diseases: lessons learned from 15-year observation at a polish referral center","volume":"60","author":"Marczak","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2026.03.001_b0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/ped.2010.0004","article-title":"Pathogenesis of interstitial lung disease in children and adults","volume":"23","author":"Glasser","year":"2010","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.prrv.2026.03.001_b0030","first-page":"18","article-title":"Pulmonary fibrosis treatment in children - what have we learnt from studies in adults?","volume":"52","author":"Jia","year":"2024","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.prrv.2026.03.001_b0035","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201903-0544CI","article-title":"Approaching clinical trials in childhood interstitial lung disease and pediatric pulmonary fibrosis","volume":"200","author":"Deterding","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2026.03.001_b0040","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1164\/rccm.201305-0923ST","article-title":"An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy","volume":"188","author":"Kurland","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2026.03.001_b0045","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/thoraxjnl-2015-207349","article-title":"European protocols for the diagnosis and initial treatment of interstitial lung disease in children","volume":"70","author":"Bush","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2026.03.001_b0050","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0004-2025","article-title":"An update on diagnosis and treatments of childhood interstitial lung diseases","volume":"21","author":"Marczak","year":"2025","journal-title":"Breathe"},{"key":"10.1016\/j.prrv.2026.03.001_b0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0065","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.prrv.2026.03.001_b0070","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.revmed.2025.04.027","article-title":"French protocol for diagnosis and management of type 1 interferonopathies","volume":"46","author":"Belot","year":"2025","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"10.1016\/j.prrv.2026.03.001_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103248","article-title":"JAK inhibitors in refractory juvenile rheumatic diseases: efficacy, tolerance and type-I interferon profiling, a single center retrospective study","volume":"147","author":"Solignac","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.prrv.2026.03.001_b0080","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1093\/rheumatology\/keaf214","article-title":"Myositis-specific autoantibody subtypes are associated with response to Janus kinase inhibitors in patients with juvenile dermatomyositis","volume":"64","author":"Bader-Meunier","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.prrv.2026.03.001_b0085","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0090","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jaip.2020.11.007","article-title":"Overview of STING-associated vasculopathy with onset in infancy (SAVI) among 21 patients","volume":"9","author":"Fr\u00e9mond","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.prrv.2026.03.001_b0095","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ng.3279","article-title":"COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis","volume":"47","author":"Watkin","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.prrv.2026.03.001_b0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/cells11030318","article-title":"Lung inflammation in STING-associated vasculopathy with onset in infancy (SAVI)","volume":"11","author":"David","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prrv.2026.03.001_b0105","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0001-2020","article-title":"Lung involvement in monogenic interferonopathies","volume":"29","author":"Cazzato","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.prrv.2026.03.001_b0110","doi-asserted-by":"crossref","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest n.d.;128:3041\u201352. https:\/\/doi.org\/10.1172\/JCI98814.","DOI":"10.1172\/JCI98814"},{"key":"10.1016\/j.prrv.2026.03.001_b0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12969-023-00817-8","article-title":"Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS\/CANDLE, SAVI, and AGS)","volume":"21","author":"Kanazawa","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.prrv.2026.03.001_b0120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031832","article-title":"Use of Tofacitinib for infant-onset STING-associated vasculopathy: a case report from China","volume":"101","author":"Shen","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.prrv.2026.03.001_b0125","article-title":"Response to two Janus kinase inhibitors in a boy with SAVI during 2-year follow-up: case report and literature review","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0130","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jaip.2024.05.017","article-title":"Baricitinib treatment in children with COPA syndrome","volume":"12","author":"Matucci-Cerinic","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.prrv.2026.03.001_b0135","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.5152\/eurjrheum.2019.18177","article-title":"Baricitinib in therapy of COPA syndrome in a 15-year-old girl","volume":"7","author":"Krutzke","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/thoraxjnl-2019-213892","article-title":"Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage","volume":"75","author":"Fr\u00e9mond","year":"2020","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2026.03.001_b0145","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.arbres.2024.04.005","article-title":"Arthritis, pulmonary cysts and renal insufficiency: COPA syndrome","volume":"60","author":"Balaguer Cartagena","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.prrv.2026.03.001_b0150","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/annrheumdis-2021-221814","article-title":"The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE\/PRAAS","volume":"81","author":"Gedik","year":"2022","journal-title":"SAVI AGS Ann Rheum Dis"},{"key":"10.1016\/j.prrv.2026.03.001_b0155","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27481","article-title":"Efficacy of ruxolitinib in severe pediatric intra-alveolar hemorrhages unrelated to COPA mutations","volume":"60","author":"Le","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2026.03.001_b0160","article-title":"Insights from a novel monogenic autoinflammatory disease: overview of a multicentric European cohort of 38 patients with COPA syndrome","author":"David","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.prrv.2026.03.001_b0165","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10875-019-00645-0","article-title":"Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome","volume":"39","author":"Volpi","year":"2019","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10875-024-01826-2","article-title":"Normalized interferon signatures and clinical improvements by IFNAR1 blocking antibody (Anifrolumab) in patients with type I interferonopathies","volume":"45","author":"Kretzschmar","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0175","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jamadermatol.2024.2160","article-title":"Successful treatment of stimulator of interferon genes-associated vasculopathy of infantile onset SAVI syndrome with anifrolumab","volume":"160","author":"Mansilla-Polo","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0180","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/art.43145","article-title":"Sustained interferon signature suppression with anifrolumab in a patient with STING-associated vasculopathy with onset in infancy refractory to JAK inhibitor and Dazukibart therapy","volume":"77","author":"Alehashemi","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0185","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis1","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0190","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103416","article-title":"Lung involvement in juvenile idiopathic inflammatory myopathy: a systematic review","volume":"22","author":"Abu-Rumeileh","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.prrv.2026.03.001_b0200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","article-title":"Interstitial lung disease in Anti-MDA5 positive dermatomyositis","volume":"60","author":"Wu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1151695","article-title":"Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103686","article-title":"The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis","volume":"23","author":"Castellini","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.prrv.2026.03.001_b0215","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.833114","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on Type I interferon system","volume":"8","author":"Hu","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.prrv.2026.03.001_b0225","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14656566.2024.2392021","article-title":"Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons","volume":"25","author":"Wallwork","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.prrv.2026.03.001_b0230","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-063268","article-title":"Successful treatment of rapidly progressive interstitial lung disease in juvenile dermatomyositis","volume":"153","author":"Ciaglia","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2026.03.001_b0235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12969-024-01044-5","article-title":"Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib","volume":"23","author":"Natoli","year":"2025","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0240","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2026.03.001_b0245","unstructured":"Priovant Therapeutics, Inc. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis. clinicaltrials.gov; 2025."},{"key":"10.1016\/j.prrv.2026.03.001_b0250","unstructured":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). A Phase II Open-Label Study of Deucravacitinib for Refractory Adults With Dermatomyositis/ Juvenile Dermatomyositis. clinicaltrials.gov; 2025."},{"key":"10.1016\/j.prrv.2026.03.001_b0255","article-title":"Multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis","author":"Randomized","year":"2025","journal-title":"Clinicaltrialsgov"},{"key":"10.1016\/j.prrv.2026.03.001_b0260","unstructured":"Assistance Publique - H\u00f4pitaux de Paris. Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis. clinicaltrials.gov; 2024."},{"key":"10.1016\/j.prrv.2026.03.001_b0265","unstructured":"Assistance Publique - H\u00f4pitaux de Paris. Baricitinib in Patients With Relapsing or na\u00efve Dermatomyositis: a Multicenter Randomized Controlled Trial (BIRD). clinicaltrials.gov; 2025."},{"key":"10.1016\/j.prrv.2026.03.001_b0270","unstructured":"First Affiliated Hospital Xi'an Jiaotong University. The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients. clinicaltrials.gov; 2021."},{"key":"10.1016\/j.prrv.2026.03.001_b0275","doi-asserted-by":"crossref","unstructured":"Antoniou KM, Distler O, Gheorghiu A-M, Moor CC, Vikse J, Bizymi N, et al. ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung diseaseDeveloped by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG). Europ Respirat J 2025. doi: 10.1183\/13993003.02533-2024.","DOI":"10.1016\/j.ard.2025.08.021"},{"key":"10.1016\/j.prrv.2026.03.001_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1717766","article-title":"Efficacy of anifrolumab on skin, joint and lung involvement in anti-MDA5 positive dermatomyositis: a case report","volume":"16","author":"Pettorossi","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0285","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/diagnostics12123095","article-title":"Lung Involvement in systemic juvenile idiopathic arthritis: a narrative review","volume":"12","author":"Petrongari","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.prrv.2026.03.001_b0290","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/acr2.11600","article-title":"Development of a screening algorithm for lung disease in systemic juvenile idiopathic arthritis","volume":"5","author":"Wobma","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0295","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12969-024-01028-5","article-title":"Clinical characteristics and prognosis of interstitial lung disease in systemic juvenile idiopathic arthritis: a two-center retrospective observational cohort study","volume":"22","author":"Zhan","year":"2024","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.prrv.2026.03.001_b0300","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0305","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.prrv.2026.03.001_b0310","article-title":"The conundrum of lung disease and drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis","volume":"74","author":"Ba","year":"2022","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.prrv.2026.03.001_b0315","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2014-05-575225","article-title":"T-cell\u2013restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lung","volume":"125","author":"Iriguchi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.prrv.2026.03.001_b0320","article-title":"The place of JAK inhibitors in systemic juvenile idiopathic arthritis with lung disease: French experience","author":"C\u00f4te","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.prrv.2026.03.001_b0325","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0152-2020","article-title":"Pulmonary granulomatosis of genetic origin","volume":"30","author":"Bode","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.prrv.2026.03.001_b0330","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1165\/ajrcmb\/1.6.439","article-title":"Cellular and molecular aspects of granulomatous inflammation","volume":"1","author":"Kunkel","year":"1989","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prrv.2026.03.001_b0335","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1172\/JCI111852","article-title":"Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis","volume":"75","author":"Robinson","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prrv.2026.03.001_b0340","doi-asserted-by":"crossref","unstructured":"Hcb L, BB, JL, Sb K, N G. Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response. Clin Exp Rheumatol 2024;42. doi: 10.55563\/clinexprheumatol\/mmzdlj.","DOI":"10.55563\/clinexprheumatol\/mmzdlj"},{"key":"10.1016\/j.prrv.2026.03.001_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.594133","article-title":"Emerging molecular targets for the treatment of refractory sarcoidosis","volume":"7","author":"Boleto","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.prrv.2026.03.001_b0350","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.prrv.2026.03.001_b0355","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1093\/rheumatology\/keaf333","article-title":"Ruxolitinib for refractory lung granulomatosis in two paediatric patients","volume":"64","author":"Michelet","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.prrv.2026.03.001_b0360","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10875-022-01353-y","article-title":"Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1\u03b2 and IL-18","volume":"43","author":"Rood","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.prrv.2026.03.001_b0365","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases","volume":"585","author":"Tanaka","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.prrv.2026.03.001_b0370","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2026.03.001_b0375","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.chest.2023.08.013","article-title":"Impact of systemic sclerosis-associated interstitial lung disease with and without pulmonary hypertension on survival: a large cohort study of the german network for systemic sclerosis","volume":"165","author":"Moinzadeh","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2026.03.001_b0380","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/rheumatology\/ken388","article-title":"Factors affecting survival in juvenile systemic sclerosis","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.prrv.2026.03.001_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152197","article-title":"Juvenile and adult-onset scleroderma: different clinical phenotypes","volume":"60","author":"Adrovic","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.prrv.2026.03.001_b0390","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.03.001_b0395","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.prrv.2026.03.001_b0400","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1513\/AnnalsATS.202301-056OC","article-title":"Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"21","author":"Ghazipura","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.prrv.2026.03.001_b0405","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00296-020-04732-z","article-title":"Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study","volume":"41","author":"Adrovic","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.prrv.2026.03.001_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100607","article-title":"A progranulin variant causing childhood interstitial lung disease responsive to anti-TNF-\u03b1 biologic therapy","volume":"6","author":"Kennedy","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.prrv.2026.03.001_b0415","article-title":"Short-term effectiveness of baricitinib in children with refractory and\/or severe juvenile dermatomyositis","volume":"10","author":"Wang","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.prrv.2026.03.001_b0420","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12969-023-00894-9","article-title":"Rapid and sustained response to JAK inhibition in a child with severe MDA5\u2009+\u2009juvenile dermatomyositis","volume":"21","author":"Strauss","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.prrv.2026.03.001_b0425","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","article-title":"Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review","volume":"60","author":"Yu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.prrv.2026.03.001_b0430","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1756-185X.14258","article-title":"Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"25","author":"Chan Ng","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.prrv.2026.03.001_b0435","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-023-03170-z","article-title":"Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China","volume":"25","author":"Zhang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.prrv.2026.03.001_b0440","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ard-2023-223919","article-title":"Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients","volume":"82","author":"Xue","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:18:55Z","timestamp":1776129535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054226000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":88,"alternative-id":["S1526054226000229"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2026.03.001","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulation in paediatric inflammatory interstitial lung diseases: towards mechanism-based targeted therapies, a focus on the anti-cytokines","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}